Optimal targeting of HER2-PI3K signaling in breast cancer

Mechanistic insights and clinical implications

Brent N. Rexer, Carlos L. Arteaga

Research output: Contribution to journalReview article

41 Citations (Scopus)

Abstract

The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2+ breast cancer by inhibiting HER2-PI3K-FOXO-survivin signaling. In this review the potential clinical implications of these findings are discussed.

Original languageEnglish (US)
Pages (from-to)3817-3820
Number of pages4
JournalCancer Research
Volume73
Issue number13
DOIs
StatePublished - Jul 1 2013

Fingerprint

Phosphatidylinositol 3-Kinases
Breast Neoplasms
Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Optimal targeting of HER2-PI3K signaling in breast cancer : Mechanistic insights and clinical implications. / Rexer, Brent N.; Arteaga, Carlos L.

In: Cancer Research, Vol. 73, No. 13, 01.07.2013, p. 3817-3820.

Research output: Contribution to journalReview article

@article{970806a8238e457e8b024a45384725a9,
title = "Optimal targeting of HER2-PI3K signaling in breast cancer: Mechanistic insights and clinical implications",
abstract = "The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2+ breast cancer by inhibiting HER2-PI3K-FOXO-survivin signaling. In this review the potential clinical implications of these findings are discussed.",
author = "Rexer, {Brent N.} and Arteaga, {Carlos L.}",
year = "2013",
month = "7",
day = "1",
doi = "10.1158/0008-5472.CAN-13-0687",
language = "English (US)",
volume = "73",
pages = "3817--3820",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Optimal targeting of HER2-PI3K signaling in breast cancer

T2 - Mechanistic insights and clinical implications

AU - Rexer, Brent N.

AU - Arteaga, Carlos L.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2+ breast cancer by inhibiting HER2-PI3K-FOXO-survivin signaling. In this review the potential clinical implications of these findings are discussed.

AB - The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2+ breast cancer by inhibiting HER2-PI3K-FOXO-survivin signaling. In this review the potential clinical implications of these findings are discussed.

UR - http://www.scopus.com/inward/record.url?scp=84880065874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880065874&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-0687

DO - 10.1158/0008-5472.CAN-13-0687

M3 - Review article

VL - 73

SP - 3817

EP - 3820

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -